BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 10765119)

  • 21. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
    Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
    Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
    Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [S-1 for gastric cancer-S-1 monotherapy and its progress].
    Shitara K; Sakata Y; Kudou T; Munakata M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():43-51. PubMed ID: 16897971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
    Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
    Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
    Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1151-8. PubMed ID: 9679577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
    Blum M; Suzuki A; Ajani JA
    Future Oncol; 2011 Jun; 7(6):715-26. PubMed ID: 21675835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of clinical results and predictors of response in chemo-naive patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy.
    Yonemori K; Shimada Y; Goto A; Ura T; Arai T; Hamaguchi T; Muro K; Yamada Y; Shirao K
    Gastric Cancer; 2004; 7(4):204-10. PubMed ID: 15616768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of liver metastasis of gastric cancer responding well to TS-1].
    Niinobu T; Yamamoto M; Taniguchi M; Kotobuki T; Otsuka A
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1674-7. PubMed ID: 15553680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
    Chollet P; Schöffski P; Weigang-Köhler K; Schellens JH; Cure H; Pavlidis N; Grünwald V; De Boer R; Wanders J; Fumoleau P;
    Eur J Cancer; 2003 Jun; 39(9):1264-70. PubMed ID: 12763215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral treatment for gastric cancer: new choices, better choices?
    Cascinu S
    Lancet Oncol; 2008 Mar; 9(3):188-9. PubMed ID: 18308239
    [No Abstract]   [Full Text] [Related]  

  • 34. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Late phase II study of S-1 in patients with advanced head and neck cancer].
    Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B;
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1381-90. PubMed ID: 11681245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
    Hara A; Tokuhara T; Takahashi Y; Izumi N; Iwamoto S; Satake K
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):601-4. PubMed ID: 15114708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
    Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
    Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
    Koizumi W; Akiya T; Sato A; Sakuyama T; Sasaki E; Tomidokoro T; Hamada T; Fujimori M; Kikuchi Y; Shimada K; Mine T; Yamaguchi K; Sasaki T; Kurihara M
    Cancer Chemother Pharmacol; 2010 May; 65(6):1093-9. PubMed ID: 19727730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
    Narahara H; Iishi H; Imamura H; Tsuburaya A; Chin K; Imamoto H; Esaki T; Furukawa H; Hamada C; Sakata Y
    Gastric Cancer; 2011 Mar; 14(1):72-80. PubMed ID: 21340666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
    Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
    Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.